Pyelonephritis in the mouse. 3. Therapeutic experiments.
D000667:Ampicillin / Q000627:therapeutic use*; D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002701:Chloramphenicol / Q000627:therapeutic use*; D007116:Immunization, Passive; D007612:Kanamycin / Q000627:therapeutic use*; D051379:Mice; D009268:Nalidixic Acid / Q000627:therapeutic use*; D009355:Neomycin / Q000627:therapeutic use*; D010080:Oxazoles / Q000627:therapeutic use; D010118:Oxytetracycline / Q000627:therapeutic use*; D010400:Penicillin G / Q000627:therapeutic use*; D011113:Polymyxins / Q000627:therapeutic use*; D011512:Proteus Infections / Q000188:drug therapy*; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011704:Pyelonephritis / Q000188:drug therapy*; D013411:Sulfadiazine / Q000627:therapeutic use*; D013444:Sulfisoxazole / Q000627:therapeutic use*
D000890:Anti-Infective Agents; D010080:Oxazoles; D011113:Polymyxins; D013411:Sulfadiazine; D009268:Nalidixic Acid; D007612:Kanamycin; D002701:Chloramphenicol; D013444:Sulfisoxazole; D000667:Ampicillin; D009355:Neomycin; D010400:Penicillin G; D010118:Oxytetracycline